Pharmacological interventions for traumatic brain injury

British Columbia Medical Journal

Volumn 53, Issue 1, 2011, Pages

  Talsky, Aaron ^a   Pacione, Laura R ^a   Shaw, Tammy ^b   Wasserman, Lori ^a   Lenny, Adam ^a   Verma, Amol ^a   Hurwitz, Gillian ^c   Waxman, Robyn ^a   Morgan, Andrew ^a   Bhalerao, Shree ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79251567967     PISSN: 00070556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Bruns J Jr, Hauser WA. The epidemiology of traumatic brain injury: A review. Epilepsia 2003;44: 2-10.
2. Okie S. Traumatic brain injury in the war zone. N Engl J Med 2005;352: 2043-2047.
3. Thurman DJ, Alverson C, Dunn KA, et al. Traumatic brain injury in the United States: A public health perspective. J Head Trauma Rehabil 14 1999;14: 602-615.
4. Woo BH, Nesathurai S (eds). The rehabilitation of patients with traumatic brain injury. Malden, MA: Blackwell Science; 2000: 5-12.
5. Bricolo A. Prolonged posttraumatic coma, In: Vinken PJ, Bruyn GW (eds). Handbook of clinical neurology Amsterdam: Elsevier; 1976: 699-755.
6. O'Dell MW, Riggs RV. Management of the minimally responsive patient. In: Horn LJ (ed). Medical rehabilitation of traumatic brain injury. Philadelphia: Hanley and Belfus; 1996: 103-131.
7. Salmond CH, Sahakian BJ. Cognitive outcome in traumatic brain injury survivors. Curr Opin Crit Care 2005;11: 111-116.
8. Hellawell DJ, Taylor RT, Pentland B. Cognitive and psychosocial outcome following moderate or severe traumatic brain injury. Brain Inj 1999;13: 489-504.
9. Arciniegas DB, The cholinergic hypothesis of cognitive impairment caused by traumatic brain injury. Curr Psychiatry Rep 2003;5: 391-399.
10. Evans RW, Gualtieri CT. Psychostimulant pharmacology in traumatic brain injury. J Head Trauma Rehabil 1987;2: 29-33.
11. Challman T, Lipsky J. Methylphenidate: Its pharmacology and uses. Mayo Clin Proc 2000;75: 711-721.
12. Whyte J, Hart T, Schuster K, et al. Effects of methylphenidate on attentional function after traumatic brain injury. Am J Phys Med Rehabil 1997;76: 440-450.
13. Kaelin C, Cifu D, Matthies B. Methyl-phenidate effect on attention deficit in the acutely brain-injured adult. Arch Phys Med Rehabil 1996;77: 6-10.
14. Speech T, Rao S, Osmon D, et al. A double blind controlled study of methylphen-idate treatment in closed head injury. Brain Inj 1993;7: 333-338.
15. Plenger P, Dixon E, Castillo R, et al. Subacute methylphenidate treatment for moderate to moderately severe traumatic brain injury: A preliminary double-blind placebo-controlled study. Arch Phys Med Rehabil 1996;77: 536-540.
16. Mooney G, Haas L. Effect of methyl-phen-i-date on brain injury-related anger. Arch Phys Med Rehabil 1993;74: 153-160.
17. Wroblewski B, Leary J, Phelan A, et al. Methylphenidate and seizure frequency in brain injured patients with seizure disorders. J Clin Psychiatry 1992;53: 86-89.
18. Evans R, Gualtieri T, Patterson D. Treatment of chronic closed head injury with psychostimulant drugs: A controlled case study and an appropriate evaluation procedure. J Nerv Ment Dis 1987;175: 110.
19. Forsyth R, Jayamoni B. Noradrenergic agonists for acute traumatic brain injury. Cochrane Database Syst Rev 2003;(1):CD003984.
20. Siddall OM, Use of methylphedinate in traumatic brain injury. Ann Pharmacother 2005;39: 1309-1313.
21. Meythaler J, Lawrence D, Devivo M, et al. Sertraline to improve arousal and alertness in severe traumatic brain injury secondary to motor vehicle crashes. Brain Inj 2000;15: 321-331.
22. Stengler-Wenzke K, Muller U. Fluoxetine for OCD after brain injury. Am J Psychiatry 2002;159: 872.
23. Muller U, Mural T, Bauer-Wittmund T, et al. Paroxetine versus citalopram treatment of pathological crying after brain injury. Brain Inj 1999;13: 808-811.
24. De Marchi R, Bansal V, Hung A, et al. Review of awakening agents. Can J Neurol Sci 2005;32: 4-17.
25. Teng C, Bhalerao S, Lee A, et al. The use of buproprion in the treatment of restlessness after a traumatic brain injury. Brain Inj 2001;15: 463-467.
26. Schneider W, Drew-Cates J, Wong T, et al. Cognitive and behavioural efficacy of amantadine in acute traumatic brain injury: An initial double-blind placebo-controlled study. Brain Injury 1999;13: 863-872.
27. Kraus M, Maki P. The combined use of amantadine and l-dopa/carbidopa in the treatment of chronic brain injury. Brain Inj 1997;11: 455-460.
28. Zafonte R, Lexell J, Cullen N. Possible applications for dopaminergic agents following traumatic brain injury: Part 1. J Head Trauma Rehabil 2000;15: 1179-1182.
29. Meythaler J, Brunner R, Johnson A, et al. Amantadine to improve neurorecovery in traumatic brain injury-associated diffuse axonal injury: A pilot double-blind randomized trial. J Head Trauma Rehabil 2002;31: 300-313.
30. Zafonte R, Watanabe T, Mann N. Amantadine: A potential treatment for the minimally conscious state. Brain Inj 1998;12: 617-621.
31. Saniova B, Drobny M, Kneslova L, et al. The outcome of patients with severe head injuries treated with amantadine sulphate. J Neur Transm 2004;111: 511-514.
32. Crismon M, Childs A, Wilcox R, et al. The effect of bromocriptine on speech dysfunction in patients with diffuse brain injury (akinetic mutism). Clin Neuropharmacol 1988;11: 462-466.
33. Anderson B. Relief of akinetic mutism from obstructive hydrocephalus using bromocriptine and ephedrine. J Neurosurg 1992;76: 152-155.
34. Passler M, Riggs R. Positive outcomes in traumatic brain injury-vegetative state: Patients treated with bromocriptine. Arch Phys Med Rehabil 2001;82: 311-315.
35. Haig A, Ruess J. Recovery from vegetative state of six months' duration associated with Sinemet (levodopa/carbidopa). Arch Phys Med Rehabil 1990;71: 1081-1082.
36. Karli D, Burke D, Kim H, et al. Effects of dopaminergic combination therapy for frontal lobe dysfunction in traumatic brain injury rehabilitation. Brain Inj 1999;13: 63-68.
37. Wroblewski B, Joseph A, Kupfer J, et al. Effectiveness of valproic acid on destructive and aggressive behaviours in pa-tients with acquired brain injury. Brain Inj 1997;11: 37-47.
38. Massagli T. Neurobehavioral effects of phenytoin, carbamazepine, and valproic acid: Implications for use in traumatic brain injury. Arch Phys Med and Rehabil 1991;72: 219-225.
39. Dikmen S, Machamer J, Winn H, et al. Neuropsychological effects of valproate in traumatic brain injury. Neurology 2000;54: 895-902.
40. Chatham-Showalter P, Kimmel DN. Agitated symptom response to divalproex following acute brain injury. J Neuropsychiatry Clin Neurosci 2000;12: 395-397.
41. Kim E, Humaran T. Divalproex in the management of neuropsychiatric complications of remote acquired brain injury. J Neuropsychiatry Clin Neurosci 2002;14: 202-205.
42. Lin J, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos im-muno-cytochemistry in the cat. Proc Natl Acad Sci U S A 1996;93: 14128-14133.
43. Ferraro L, Antonelli T, Tanganelli S. The vigilance promoting drug modafinil in-creases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: Prevention by local GABAA receptor blockade. Neuropsychopharmacology 1999;20: 346-356.
44. Saletu B, Saletu M, Grunberger J, et al. Treatment of the alcoholic organic brain syndrome: Double-blind, placebo-controlled clinical, psychometric and electroencephalographic mapping studies with modafinil. Neuropsychobiology 1993;27: 26-39.
45. Teitelman E. Off-label uses of modafinil. Am J Psychiatry 2001;158: 1341.
46. Fleminger S, Greenwood RJ, Oliver DL. Pharmacological management for agitation and aggression in people with acquired brain injury. Cochrane Database Syst Rev 2003;(1):CD003299.
47. Feeney DM, Gonzalez A, Law WA. Amphetamine, haloperidol and experience interact to affect the rate of recovery after motor cortex injury. Science 1982;217: 855-857.
48. Goldstein LB. Common drugs may influence motor recovery after stroke. Neurology 1995;45: 865-872.
49. Schallert T, Hernandez T, Barth T. Recovery of function after brain damage: Severe and chronic disruption by diaze-pam. Brain Res 1986;379: 104-111.
50. Brailowsky S, Knight RT, Efron R. Phenytoin increases the severity of cortical hemiplegia in rats. Brain Res 1986;376: 71-77.
51. Goldstein LB. Influence of common drugs and related factors on stroke outcome. Curr Opin Neurol 1997;10: 52-57.
52. Zhang L, Plotkin RC, Wang G, et al. Cholinergic augmentation with donepezil enhances recovery in short-term memory and sustained attention after traumatic brain injury. Arch Phys Med Rehabil 2004;85: 1050-1055.
53. Walker W, Seel R, Gibellato M, et al. The effects of donepezil on traumatic brain injury acute rehabilitation outcomes. Brain Inj 2004;18: 739-750.
54. Levy M, Berson A, Cook T, et al. Treatment of agitation following traumatic brain injury: A review of the literature. NeuroRehabilitation 2005;20: 279-306.